ERAS — what changed in the latest 10-Q
A section-by-section comparison of ERAS's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-11 vs the prior 10-Q · 2026-05-11
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +48 | −19 | ~8 | 94 |
| Market risk (Item 3) | Text added/removed | 0 | 0 | ~1 | 0 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 1 |
| Legal proceedings | Text added/removed | +3 | −1 | 0 | 0 |
| Risk factors | Some risk factors updated | +2 | 0 | 0 | 3 |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-11
On July 13, 2026, we announced updated preliminary Phase 1 data for ERAS-0015 in patients with RAS-mutant solid tumors from our ongoing AURORAS-1 Phase 1 trial in the United States that builds on our April 2026 announcement, with additional patients and longer follow-up.
Encouraging Monotherapy Responses Observed in 2L+ KRAS G12X PDAC1
Across doses, all patients with either confirmed or unconfirmed responses remained on treatment
At RDE of 32 mg QD, 6 of 7 enrolled patients remained on treatment; at RDE of 24 mg QD, 6 of 8 enrolled patients remained on treatment
With Additional Patients and Longer Follow-up, Monotherapy Safety Data Remained Consistent with Prior Disclosure and ERAS-0015 Continued to be Generally Well-Tolerated1
Text removed vs the prior filing · source: 10-Q · 2026-05-11
The following figure shows the RAS/MAPK pathway and how the three therapeutic strategies listed above attempt to comprehensively and synergistically shut down the RAS/MAPK pathway.
In May 2025, in connection with our expectation that ERAS-0015 and ERAS-4001 would both become clinical stage programs, we conducted a broader pipeline review. Following this review, in order to prioritize organizational focus and resources to advance our differentiated RAS-targeting franchise, we d…
Since our inception in 2018, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, identifying, acquiring, and in-licensing our product candidates, establishing our intellectual property portfolio, conducting research, preclini…
We have incurred significant operating losses since inception. Our net losses were $183.4 million and $31.0 million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, we had an accumulated deficit of $1.1 billion. We expect our expenses and operating losses will …
Based upon our current operating plans, we believe that our cash, cash equivalents, and marketable securities as of March 31, 2026 will be sufficient to fund our operations into the second half of 2028. We do not expect to generate any revenues from product sales until we successfully complete devel…
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-11
On June 10, 2026, a purported securities class action complaint was filed against us and certain of our officers in the United States District Court for the Southern District of California. The complaint alleges violations of the federal securities laws and seeks damages, costs, and other unspecifie…
In August 2026, a putative stockholder derivative complaint was filed in the United States District Court for the Southern District of California, captioned ES Trust v. Lim, et al., Case No. 3:26-cv-04517-WQH-JAC. The complaint named us as a nominal defendant and our current directors and Chief Fina…
From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors,…
Text removed vs the prior filing · source: 10-Q · 2026-05-11
We are not currently a party to any material proceedings. From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and s…
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-11
We are subject to securities class action litigation and a stockholder derivative complaint, and may become subject to additional litigation, which could result in substantial costs and divert management's attention.
On June 10, 2026, a purported securities class action complaint was filed against us and certain of our officers in the United States District Court for the Southern District of California. The complaint alleges violations of the federal securities laws and seeks damages, costs, and other unspecifie…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice